The Opioid Epidemic in Philadelphia

Implementation of the Mayor’s Task Force Recommendations

Status Report to Mayor’s Commission on Addiction and Recovery
October 10, 2018

Thomas Farley, MD, MPH
Commissioner
Philadelphia Department of Public Health

David T. Jones
Commissioner
Department of Behavioral Health and Intellectual disAbility Services
Drug overdoses continue to cause 250-300 deaths each quarter.

Number of Drug-Related Overdose Deaths by Quarter, 2010 – 2018Q1

* 2018 Q2 data have not been finalized
The City has taken many actions to reduce the harmful effects of opioid use and overdose

<table>
<thead>
<tr>
<th>Prevention and Education</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Media campaigns</td>
<td>• Expansion of treatment programs</td>
</tr>
<tr>
<td>• Health care provider education</td>
<td>• “Warm handoffs”</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Criminal Justice System</th>
<th>Harm Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Treat addiction in jail</td>
<td>• Naloxone distribution</td>
</tr>
<tr>
<td>• Overdose education and naloxone distribution</td>
<td>• Overdose Prevention Services</td>
</tr>
</tbody>
</table>
Progress highlights since the June 2018 status report
New Opioid Website

Combating the opioid epidemic
Fighting back against the opioid crisis in Philadelphia.

www.phila.gov/opioids
Highlights for Prevention Recommendations

Discontinuing Opioids for Chronic, Non-Cancer Pain

**Discontinuing Use**

1. Establish the role of taper:
   a. Immediate discontinuation if there is evidence of diversion.
   b. Rapid taper (over 2-3 weeks) if the patient has had a severe adverse outcome (i.e., overdose or substance use disorder).
   c. Slow taper if there are no acute safety concerns. Start with a 10% taper of the original dose per week, and declare the patient pain and functional status. For patients who have been on opioids for more than 3 years, tapering every two weeks or even months can be considered.
   d. Seek specialty care for pregnant patients as opioid withdrawal during pregnancy has been associated with spontaneous abortion and premature labor.

2. Adjust the rate, intensity, and duration of taper based on the patient's response and development of withdrawal symptoms. Patients using short-acting opioids (e.g., oxycodone) can experience withdrawal symptoms within 12 hours of the last dose. The onset of symptoms may be later for patients using long-acting opioids (e.g., OxyContin). Withdrawal symptoms might include increased sympathetic activity, and commonly include anxiety, palpitations, restlessness, tension, sweating, nausea, abdominal pain, diarrhea, shivering, and vomiting. Reducing the taper by less than 10% per week can minimize withdrawal symptoms. Patients should be informed that general malaise and other symptoms of mild withdrawal may persist up to a month following opioid cessation.

3. Use medications to treat opioid withdrawal symptoms if needed. These include clonidine (for tremors, sweating, or tremor), an anticholinergic (risperidone), and meperidine (for anxiety). Provided there are no contraindications. Do not use benzodiazepines to treat anxiety or restlessness.

4. Monitor for psychiatric disorders during the taper and consult a behavioral health specialist as needed. If a patient expresses suicidal ideation, refer to a crisis response center, emergency department, or urgent evaluation by a behavioral health specialist.

5. Do not reverse the taper. The rate may be slowed or paused while monitoring for and treating withdrawal symptoms, as well as addressing psychiatric disorders.

6. In patients taking both opioids and benzodiazepines, taper opioids before tapering benzodiazepines. When tapering benzodiazepines, start with a 20% reduction over 2 weeks and monitor for signs and symptoms of withdrawal.

7. Consider impaired withdrawal management or maintenance with Suboxone (buprenorphine/naloxone) if the patient has pre-existing opioid cravings.

8. Do not resume opioids or benzodiazepines once they have been stopped, as they may trigger drug cravings and a return to use.

**PAIN MANAGEMENT**

**Key Recommendations for Dentists**

- Administer NSAIDs as first line analgesic therapy.
- Use acetaminophen with NSAIDs for additional pain relief.
- Use of opioids for acute dental pain is strongly discouraged.

**THINK NSAIDS**
Opioid prescribing is declining 5-8% per quarter

Number of opioid prescriptions written for Phila residents (excluding buprenorphine), 2016 Q3 - 2018 Q1
Highlights for Overdose Prevention and Harm Reduction Recommendations

Since the Task Force, the City has:

• Distribute over **57,000 doses** of naloxone to individuals at high risk of an opioid-related overdose

• Trained **nearly 2,000 persons** in overdose management and naloxone use

- [http://www.phillynaloxone.com](http://www.phillynaloxone.com)
The City is encouraging the development of one or more overdose prevention sites (OPS)

- Identify organization(s) to operate OPS (Safehouse)
- Find funding – in progress
- Identify location(s)
- Explore legal issues – in progress
- Meet with stakeholders & community members – in progress
Expanding Treatment Capacity:

DBH-Funded Recovery House Network was expanded with the addition of One Day at a Time (ODAAT) 2 – 40 bed Recovery House for men and women.

Halfway House capacity will be increased with 3 new specialty programs.

Exploring an ambulatory stabilization program at University of Pennsylvania Health System.

Highlights for Treatment Recommendations
First Step Staffing has secured full-time positions for 46 individuals with a history of homelessness, substance use, and/or incarceration.

Pilot to incorporate withdrawal management into the Journey of Hope Project has been approved.
MAT inductions are occurring in three Emergency Departments.

50 individuals experiencing homelessness from Journey of Hope and Safe Haven programs have been matched to supportive housing.

Launched a monthly MAT Learning Collaborative which will run in accordance with the MAT policies to be implemented by January 2020.

- Next meeting will feature Dr. Kyle Kampman on October 31st.
Number and Rate of Distinct MA Beneficiaries with a Primary Diagnosis of OUD Participating in Buprenorphine-Based MAT, 2015-Q1 to 2018-Q2
### Increased Medication-Assisted Treatment Capacity

**36 Provider Agencies** Operating 72 Locations

**Total MAT Capacity** – 12,836 slots

- a. Total Occupied MAT Capacity – 9,498 slots
- b. Total Available MAT Capacity – 3,338 slots
- c. Available MMT Capacity – 1,285 slots
- d. Available Non-MMT Capacity (Buprenorphine, Vivitrol) – 2,053 slots

**Program Types** Outpatient, Intensive Outpatient, Residential, Partial Hospitalization, Withdrawal Management, and Centers of Excellence

**Total MAT Capacity**
- 74% occupied
- 26% available
NET 24/7 Access Point is now accepting members with a full range of substance use disorders and withdrawal symptoms for assessment, stabilization, and referral to appropriate level of care with warm hand-off.
Highlights for Criminal Justice Recommendations

- The Office of Criminal Justice, DBH, the First Judicial District, the District Attorney’s Office, and the Defender Association are examining existing court-based diversion programs to determine if expansion or creation of a new program can most effectively address opioid use disorder.
- This year one enforcement initiative has been conducted in June resulting in 166 total arrests. A second initiative occurred October 3-6, 2018.
- The Real Time Crime Center maintains records of overdose incidents in order to determine surges in overdoses and deploy law enforcement resources appropriately.
Highlights for Criminal Justice Recommendations

• Began offering buprenorphine to all inmates at PDP, expanding from a successful pilot at Riverside Correctional Facility
• Makes post-release drug treat appointments for sentenced individuals with OUD
• Expanded eligibility for inmates to receive assistance in enrolling in Medical Assistance (activated at discharge)
• Expanded eligibility for Narcan to include all patients who need medical management of withdrawal (distribute ~6,000 kits annually)